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Abstract
Background: Allosteric ribozymes (aptazymes) that have extraordinary activation parameters
have been generated in vitro by design and selection. For example, hammerhead and ligase
ribozymes that are activated by small organic effectors and protein effectors have been selected
from random sequence pools appended to extant ribozymes. Many ribozymes, especially self-
splicing introns, are known control gene regulation or viral replication in vivo. We attempted to
generate Group I self-splicing introns that were activated by a small organic effector, theophylline,
and to show that such Group I aptazymes could mediate theophylline-dependent splicing in vivo.
Results: By appending aptamers to the Group I self-splicing intron, we have generated a Group I
aptazyme whose in vivo splicing is controlled by exogenously added small molecules. Substantial
differences in gene regulation could be observed with compounds that differed by as little as a single
methyl group. The effector-specificity of the Group I aptazyme could be rationally engineered for
new effector molecules.
Conclusion: Group I aptazymes may find applications as genetic regulatory switches for generating
conditional knockouts at the level of mRNA or for developing economically viable gene therapies.
Background
Ribozymes whose activities are modulated by effector
molecules have previously been engineered. For example,
Herschlag and co-workers have previously shown that a
nucleobase could complement an abasic site within the
hammerhead ribozyme, restoring cleavage activity [1].
Similarly, Porta and Lizardi engineered a hammerhead ri-
bozyme that assumed an inactive secondary structure;
upon the addition of an oligonucleotide that disrupted
the engineered secondary structure, the ribozyme was ac-
tivated [2]. More recently, it has previously been shown
that many selected nucleic acid binding species (aptam-
ers) undergo conformational changes upon ligand bind-
ing [3–6] In addition, when aptamers are conjoined to
ribozymes, the ligand-induced conformational changes in
the aptamers frequently modulate the structures and
hence the activities of the ribozymes [7–9] For example,
binding of theophylline to the anti-theophylline aptamer
[10] modulates the conformation of residue [11,12] and
the overall stability of the aptamer [10,13]. Appending the
anti-theophylline aptamer to the hammerhead ribozyme
allowed cleavage activity to be modulated by 110-fold by
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theophylline [13]. Similarly, appending the anti-theo-
phylline aptamer to a small ribozyme ligase (L1) generat-
ed an aptazyme that was activated 1,600-fold by
saturating theophylline concentrations [14].
The methods for engineering and selecting Group I
aptazymes appear to be generalizable to several different
types of ribozymes. Adjoining aptamers to the Group I
self-splicing intron would potentially allow the control of
splicing not only in vitro, but in vivo. To this end, we have
attempted to generate and assay Group I aptazymes.
Results and Discussion
Design of Group I aptazymes
In order to convert the Group I self-splicing intron to a
regulatable aptazyme, it was necessary to first identify se-
quences or structures in the ribozyme whose conforma-
tion might modulate splicing activity. The structural and
kinetic properties of the Group I self-splicing intron from
the thymidylate synthase (td) gene in bacteriophage T4 have
been extensively studied. In particular, a series of nested
deletions of the P6 stem-loop have been shown to partial-
ly or completely compromise ribozyme activity [15].
More importantly, either magnesium or the tyrosyl tRNA
synthetase from Neurospora mitochondria (CYT18) can
suppress many of these defects [16,17]. Previous studies
with other introns have also revealed that deletion of the
P5 stem-loop can modulate ribozyme activity [18,19]. We
hypothesized that sites where deletions modulated ri-
bozyme activity might also prove to be sites where aptam-
er conformational changes would modulate ribozyme
activity. Based on these studies, we designed a series of
Group I aptazymes in which the anti-theophylline aptam-
er was substituted for either a portion of P6 or P5 (Figure
1). The anti-theophylline aptamer was attached at the
same point as had previously proven successful in the de-
sign of theophylline-dependent cleavases and ligases
[13,14].
Activation in vitro
The self-splicing activities of the Group I aptazymes were
examined in vitro using a standard splicing assay (Table 1).
Magnesium had previously been shown to suppress struc-
tural defects in the td intron, and ligand-induced suppres-
sions of splicing defects were examined by carrying out
splicing reactions at either low (3 mM, stringent) or high
(8 mM, permissive) magnesium concentrations [15]. Sev-
eral of the constructs were either relatively inactive (e.g.,
Th3P6, Th5P6, and Th6P6) or did not consistently show
differential splicing activity (e.g., Th4P6 and Th2P5).
However, four of the constructs, Th1P6, Th2P6, Th3P6,
and Th1P5, showed good activity (>10% of wild-type)
and increased self-splicing in the presence of theophyl-
line. For example, Th2P6 showed the greatest activation
(8-fold at 8 mM MgCl2), while Th1P5 showed low activa-
tion (1.2-fold) at both magnesium concentrations.
For all of the aptazymes except Th3P6, the ligand-induced
splicing activity was greater in a standard assay at the more
stringent (3 mM) magnesium concentration (Table 1).
The construct Th3P6 was inactive at lower magnesium
concentrations, but underwent ligand-induced splicing at
the more permissive concentration (8 mM). Interestingly,
those aptazyme constructs that showed ligand-dependent
activity closely resembled the original deletion variants
that showed magnesium-dependent recovery of splicing
activity. For example, the junction between the aptamer
and the Group I ribozyme in the aptazyme Th2P6 resem-
bled the deletion variant td ∆P6-6; the aptazyme was acti-
vated by theophylline, while the splicing defect of the
deletion variant at 3 mM magnesium was suppressed by 8
mM magnesium or by stabilization of a tetraloop se-
quence that capped the P6 helix [15]. Defects that poise a
ribozyme between active and inactive conformers have
previously been used to engineer effector-dependence
[20].
The kinetics of splicing of two of the most activated vari-
ants, Th1P5 and Th2P6, were examined in the presence
and absence of theophylline (Figure 2). As in the single
point assays, the theophylline-dependence of the engi-
neered introns was readily apparent (Figure 2a). The time
courses reveal that the extents of splicing of the aptazymes
were significantly affected by the addition of theophylline
(Figures 2b,2c). The aptazyme modified at P5 (Th1P5)
showed less theophylline-dependent enhancement of the
extent of reaction than the aptazyme modified at P6
(Th2P6), consistent with the single point assays described
above. Th1P5 was activated 1.4-fold at 15 minutes (Figure
2b), while Th2P6 showed a 4.0-fold rate enhancement at
Table 1: Relative in vitro splicing activity of constructs containing 
anti-theophylline aptamers. Extent of reaction is relative to the 
parental construct in 3 mM MgCl2 with no theophylline at 2 hrs.
[Mg Cl2]3  m M 8  m M
[Theo] 1.5 mM 0 mM 1.5 mM 0 mM
Parental 0.85 1 0.61 0.68
B11 0.03 0.02 0.31 0.34
Th1P6 0.2 0.05 0.31 0.16
Th2P6 0.15 0.04 0.31 0.04
Th3P6 0.03 0.04 0.2 0.04
Th4P6 0.06 0.05 0.38 0.37
Th5P6 0.04 0 0.05 0.03
Th6P6 0.03 0.01 0 0.03
Th1P5 1.08 0.91 0.85 0.74
Th1P5 0.03 0.03 0.7 0.57BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/21
Page 3 of 12
(page number not for citation purposes)
Figure 1
Theophylline-dependent td group I intron constructs. a) The figure shows the predicted secondary structure and terti-
ary interactions of the 265 nt deletion construct[15,41] of the td intron drawn in the format of Cech et al. (1994)[42] The
intron is in uppercase and the exons are in lower case letters. The 5' and 3' splice sites are indicated by arrows. The P4-P6
domain is boxed. b) The B11 construct was based on the ∆ 85–863 deletion mutant[15] of the td intron which showed no
activity in vivo or at low Mg2+ (3 mM) in vitro. An anti-theophylline aptamer, highlighted in gray, was substituted for the P6a stem
of the intron in constructs Th1P6, Th2P6, Th3P6, Th4P6, Th5P6 and Th6P6, and for the P5 stem in constructs Th1P5 and
Th2P5. Mutations in the anti-theophylline aptamer are boxed in black for constructs MeX2P6 and Th2P6.D. The C-to-A muta-
tion in MeX2P6 changes specificity from theophylline to 3-methylxanthine [34]. The A-to-U and C-to-U mutations in Th2P6.D
abolish theophylline-binding [11,43].
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Figure 2
In vitro activation of td group I aptazymes by theophylline. a) Autoradiogram showing the splicing activity of the paren-
tal, B11, Th1P6, Th2P6 and Th1P5 intron constructs in the presence and absence of 1.5 mM theophylline. LI, linear intron; CI,
circular intron; E1–E2, exon 1–exon 2 ligation product; Crp, cryptic ligation product; pre-mRNA, unspliced mRNA. b) Kinetics
of splicing for Th1P5. c) Kinetics of splicing for Th2P6. For both figures, solid circles represent the reaction in the presence of
1.5 mM theophylline and open circles represent the reaction in the absence of theophylline. Data points are the average of four
determinations.
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15 minutes (Figure 2c). These levels of ligand-dependent
activation were similar to those observed with the original
hammerhead aptazyme constructs,[21] and it may prove
possible to use in vitro selection to further optimize activa-
tion [13,14]. However, when the time course data were fit
with a single exponential equation, the rates of the initial
reactions turned out to be very similar in both the pres-
ence and absence of theophylline (Table 2).
Based on these results, the primary mechanism of activa-
tion is likely the same as has been observed for other
aptazymes: ligand-induced conformational changes that
stabilize functional ribozyme sequences and structures.
However, the Group I self-splicing intron is a much more
complicated ribozyme than either the hammerhead or the
L1 ligase; for example, the tertiary structure of the Group
I intron is established by a complicated folding pathway.
[22–26] Therefore, it was possible that theophylline-bind-
ing influenced the overall folding pathway of the engi-
neered Group I aptazyme. In order to assess this
possibility we examined the theophylline-dependence of
Th2P6 splicing reactions in vitro following prolonged in-
cubation (30 minutes) to allow for re-folding. No signifi-
cant change in the extent of ligand-dependent activation
was observed following pre-incubation (data not shown).
These results argue that both GTP and theophylline may
need to be present to influence the folding pathway of the
engineered Group I aptazymes. These results are also con-
sistent with previous physical[27] and kinetic [28–30]
data that shows that the folding of the Group I intron is
dependent in part upon GTP.
Gene regulation in vivo
Each of the successful aptazyme constructs was subse-
quently cloned into an interrupted thymidylate synthase
gene in place of the parental td self-splicing intron. The
vectors were introduced into an E. coli strain
(C600ThyA::KanR) that lacked a functional thymidylate
synthase gene and that was a thymidine auxotroph. When
bacteria grown in rich media were subsequently plated on
minimal media lacking thymidine, no colony growth was
observed with the exception of Th1P5. However, when
theophylline (7.5 mM) was included in the minimal me-
dia, bacteria containing the intron Th2P6 formed colo-
nies, and bacteria containing the intron Th1P5 showed
increased growth (Figure 3). All introns that originally
showed no or low splicing in vitro (including Th3P6)
could not rescue bacteria either in the presence or absence
of theophylline. Finally, no growth was observed in a neg-
ative control that contained a non-functional Group I in-
tron (B11), and no theophylline-dependent changes in
growth were observed in a negative control in which mu-
tations were introduced into the aptazyme to abolish the-
ophylline binding (Th2P6.D). Interestingly, no growth
was observed for bacteria harboring the intron Th1P6, de-
spite the fact that this aptazyme showed the greatest acti-
vation by theophylline in vitro. The plating results were
consistent and reproducible over a variety of experiments.
To better characterize the influence of the effector on in-
tron-splicing, we also carried out a series of growth exper-
iments in liquid culture (Figure 4a). An overnight
bacterial culture that contained the td gene divided by the
aptazyme Th2P6 was inoculated into fresh, minimal me-
dia, effector was added, and growth was continuously
monitored. As expected based on growth assays on solid
media, little growth was observed in the absence of theo-
phylline. However, when theophylline (0.5 mM) was
added to liquid medium, bacteria grew almost as well as a
control in which the parental intron was inserted into the
td gene. Most importantly, bacterial growth was not acti-
vated by the structurally-related effector caffeine (i.e., 7-
methyltheophylline); the anti-theophylline aptamer is
known to discriminate between caffeine and theophylline
by a factor of 10,000-fold [10]. No effector-dependent
Table 2: Kinetic rate constants for constructs containing anti-the-
ophylline aptamers. Rate constants were calculated based on the 
data shown in Figures 2b and 2c, and the equations presented in 
Methods.
k1 (per hour) Standard Error R-Squared
Th1P5+ 14 0.0056 0.99
Th1P5- 42 0.24 0.96
Th2P6+ 50 0.15 0.99
Th2P6- 50 0.58 0.88
Figure 3
In vivo splicing activity. The parental, B11 and theophylline
constructs were spotted in the presence and absence of 7.5
mM theophylline on minimal media (MM).
ctor
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Figure 4
Theophylline-dependent growth. Relative growth curves are shown for C600:ThyA cells containing either Th2P6 (a) and
Th1P5 (b) in the presence (black filled circles) and absence (black open circles) of 0.5 mM theophylline or 0.5 mM caffeine
(black diamonds). Parental (grey filled squares) and B11 (grey open squares) controls were grown in the 0.5 mM theophylline
for comparison. Plots are standardized to the extent of growth of cells containing the parental intron. Each point represents
the average of three replicate growth curves. c) Extent of growth at 12 hours for parental, Th2P6 and Th1P5 introns over a
range of theophylline concentrations. Background growth (B11) has been subtracted, and results are standardized to parental
growth with no theophylline.
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growth differences were observed with cultures containing
td genes divided by the non-functional Group I intron
B11. Similar results were obtained with cultures that con-
tained the td gene divided by the aptazyme Th1P5 (Figure
4b). However, in this instance there was some back-
ground growth of uninduced bacteria, consistent with the
higher level of background splicing activity in vitro. If the-
ophylline is regulating intron splicing in vivo, then the ex-
tent of bacterial growth should be dependent upon the
concentration of theophylline introduced into the media
(Figure 4c). However, theophylline was toxic to bacteria,
and caused a decrease in the growth of bacteria containing
the parental td intron at concentrations greater than 0.5
mM. Consistent with this observation, low concentrations
of theophylline progressively increased bacterial growth
(by activating the td intron) while concentrations of theo-
phylline above 2 mM progressively decreased bacterial
growth (although levels of growth were still well above
background).
These results were all consistent with the hypothesis that
theophylline regulates intron splicing in vivo. To further
probe whether this was in fact the case mRNA was isolated
from E. coli treated with theophylline or not, and RT-PCR
was used to confirm the presence of spliced introns (Fig-
ure 5). For each of the introns known to be responsive to
theophylline in vivo (Th2P6 and Th1P5) an increase in
spliced mRNA was observed, while most other introns
that were not responsive to theophylline in vivo did not
show an increase in the levels of spliced mRNA. An excep-
tion to this was Th1P6, which originally showed theo-
phylline-dependent splicing in vitro and also showed
theophylline-dependent splicing in vivo. However, Th1P6
did not mediate theophylline-dependent growth. The bac-
terial mRNAs were extracted, cloned, and sequenced, and
half of them appeared to use a cryptic splice site.
Several discrepancies were noted between intron activa-
tion in vitro and effector-dependent growth. This is not
surprising; other studies have revealed that there is often
little correlation between ribozyme activity in vitro and in
vivo [31]. However, since it is known that relatively small
changes in gene expression can greatly affect the metabo-
lism of an organism, another possible explanation for the
apparent discrepancies is that relatively small modula-
tions in intron splicing are amplified via cellular metabo-
lism to yield growth phenotypes. This would seem
especially true in the current set of experiments, since the
modulation of Thymidylate Synthase expression is known
to greatly affect thymidine levels and cell growth [32]. For
example, E. coli that are starved for thymine quickly die, a
phenomenon known as 'thymineless death' [33]. In this
respect, Group I aptazymes that may have yielded lower
amounts of functional Thymidylate Synthase (e.g.,
Th3P6, which was less active than Th2P6; or Th1P6,
which mis-spliced) did not allow bacterial growth. In con-
trast, aptazymes that may have yielded even modestly
greater amounts of functional Thymidylate Synthase (e.g.,
Th1P5, which was both highly active and modestly acti-
vated in vitro) allowed bacterial growth.
Effector specificity
In order to examine effector-specificity in vivo, a new series
of Group I aptazymes was constructed in which the anti-
theophylline aptamer was mutated to bind 3-methylxan-
thine (3MeX2P6) [34]. These variants proved to be re-
sponsive to 3-methylxanthine both in vitro and in vivo
(Figure 6a). However, the variants were no longer respon-
sive to theophylline, nor were they responsive to a variety
of other analogues, including caffeine, 1-methylxanthine,
7-methylxanthine, 1,3-dimethyl urilic acid, hypoxan-
thine, xanthine, and theobromine (Figure 6b). In con-
trast, the original aptamer was known to also bind 3-
methylxanthine, and the original Group I aptazyme
(Th2P6) also proved to be responsive to 3-methylxan-
thine in vivo (Figure 6c). Thus, the responsivity of the
aptazymes in vivo appears to mirror their effector specifici-
ty in vitro.
Figure 5
RT-PCR analysis of whole cell RNA. Bands correspond-
ing to spliced and unspliced mRNAs are indicated. The upper
set of RT-PCR reactions was seeded with RNA from cells
grown in the absence of theophylline. The lower set was
seeded with RNA from cells grown in the presence of 0.5
mM theophylline.
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Applications
The ability to engineer Group I introns to be responsive to
effector molecules has numerous potential applications.
For example, it may prove possible to develop new gene
therapies in which patients rely upon drugs that can dif-
ferentially activate gene expression, rather than having to
rely upon a set level of endogenous expression of an intro-
duced gene. Similarly, it may prove possible to use effec-
tor-dependent splicing to more finely monitor gene
expression in vivo. A drug could be localized to particular
organs, cells, or organelles, and splicing of the aptazyme
could be monitored via a reporter gene such as luciferase.
It is also possible to imagine that engineered introns in-
troduced into reporter genes may find application in high-
throughput, cell-based screening assays that monitor drug
uptake or efficacy. These strategies should prove useful
not only for self-splicing introns activated by drugs, but
for introns activated by proteins or peptides. In this re-
gard, it is notable that some natural Group I introns have
proven to be highly dependent upon protein cofac-
Figure 6
3-Methylxanthine dependent growth. a) Relative growth curves are shown for C600:ThyA cells containing 3MeX2P6 in
the presence (black filled circles) and absence (black open circles) of 1 mM 3-methlyxanthine or 1 mM theophylline (black dia-
monds). Parental (grey filled squares) and B11 (grey open squares) controls were also grown in 1 mM 3-methylxanthine. Plots
are standardized to the extent of growth of cells containing the parental intron. Each point represents the average of three
replicate growth curves. b) Specificity of growth of 3MeX2P6 on theophylline analogs. Background growth (B11) has been sub-
tracted, and results are standardized to parental growth on minimal media at 12 hrs. Negative values were not greater than -
0.05, and were set to zero. Each analog was present in the media at 0.5 mM. c) Specificity of growth of Th2P6 on theophylline
analogs. Presentation of the data is the same as in Figure 6b. Each analog was present in the media at 0.5 mM.
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tors,[35] and that Group I introns have been engineered
whose tertiary structure and activity is dependent upon a
peptide [36]. Such applications could also be melded with
other innovations dependent upon the Group I self-splic-
ing intron, such as the introduction of a trans-splicing in-
tron that can potentially repair or modulate the
expression of a given mRNA. [37–39]
Conclusions
Group I aptazymes that were dependent upon theophyl-
line both in vitro and in vivo were engineered by conjoin-
ing the thymidylate synthase (td) intron with an anti-
theophylline aptamer. Although the in vitro activation of
splicing was modest (up to an 18-fold change in initial
rate), this change was more than enough to mediate the
survival of a thymidine-dependent E. coli strain. The lig-
and specificity of the anti-theophylline aptamer carried
over to the theophylline-dependent aptazyme, and no ac-
tivation was seen with caffeine, which differed by a single
methyl group from theophylline. The effector specificity
could be rationally changed by changing the specificity of
the conjoined aptamer: when a mutation was introduced
into the anti-theophylline aptamer that led to discrimina-
tion against theophylline and in favor of 3-methylxan-
thine (that also differed from theophylline by a single
methyl group), the aptamer became solely responsive to
3-methylxanthine in vivo. Group I aptazymes may have a
number of important biotechnology applications, includ-
ing use as in vivo, real-time reporters and as regulatable
gene therapeutics.
Methods
E. coli strains and growth media
E. coli strain C600ThyA::KanR was used for the plate as-
says and in vivo growth curves. INVaF' (Invitrogen,
Carlsbad, CA) was used for cloning and plasmid amplifi-
cation. Bacterial starter cultures were grown in LB supple-
mented with thymine (50 mg/l). Screening for thymidine
auxotrophy was done in minimal media supplemented
with 0.1% Norit A-treated casamino acids (MM) and MM
supplemented with thymine (50 mg/l) (MMT). Plates
contained Bacto agar (1.5%). Ampicillin (50 mg/l) and
kanamycin (100 mg/l) were added to all growth media.
Construction of the td intron aptazymes
The wild type plasmid pTZtd1304 [17] contains a fully
functional 265 nt derivative of the 1016 nt wild type in-
tron [15]. This derivative also contains the substitutions
U34A, which introduces a SpeI site, and U976G, which in-
troduces an EcoRI site. The constructs were made using
standard solid phase DNA synthesis, then were PCR-am-
plified and cloned into pTZtd1304. The parental P6
aptazyme construct was generated by two overlapping ol-
igos, Gp1Wt2 Gp1Wt2.122 (GCC TGA GTA TAA GGT
GAC TTA TAC TTG TAA TCT ATC TAA ACG GGG AAC
CTC TCT AGT AGA CAA TCC CGT GCT AAA TTG TAG
GAC TGC CCG GGT TCT ACA TAA ATG CCT AAC GAC
TAT CCC TT) and Gp1Wt3.129 (TAA TCT TAC CCC GGA
ATT ATA TCC AGC TGC ATG TCA CCA TGC AGA GCA
GAC TAT ATC TCC AAC TTG TTA AAG CAA GTT GTC TAT
CGT TTC GAG TCA CTT GAC CCT ACT CCC CAA AGG
GAT AGT CGT TAG). These oligonucleotides (100 pmole)
were annealed and extended with AMV reverse tran-
scriptase (Amersham Pharmacia Biotech, Piscataway, NJ;
45 units) in AMV RT buffer (50 mM Tris-HCl, pH 8.3, 8
mM MgCl2, 50 mM NaCl, 1 mM DTT) and dNTPS (200
µM) for 30 minutes at 37°C. The resulting double-strand-
ed DNA was diluted 1:50 and amplified using primers
SpeI.24 (TTA TAC TAG TAA TCT ATC TAA ACG; 0.4 µM)
and EcoRI.24 (CCC GGA ATT CTA TCC AGC TGC ATG;
0.4 µM) in PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM
KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 0.005% gelatin),
dNTPS (200 µM) and Taq DNA polymerase (Promega,
Madison, WI; 1.5 units). The reactions were thermocycled
15 times at 94°C for 30 seconds, 45°C for 30 seconds,
72°C for 1 minute and then purified with a QIAquick PCR
purification kit (Qiagen, Valencia, CA). The PCR product
was digested with SpeI (New England Biolabs, Beverly,
MA; 20 units) and EcoRI (50 units) in buffer (50 mM Na-
Cl, 100 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.025% Tri-
ton X-100, 100 µg/ml BSA) at 37°C for 60 minutes,
purified, and cloned into SpeI/EcoRI digested pTZtd1304.
The negative control and aptazyme constructs were made
as described except that Gp1Wt3.129 was replaced with
oligonucleotides of the appropriate sequence: B11 GCC
TGA GTA TAA GGT GAC TTA TAC TTG TAA TCT ATC TAA
ACG GGG AAC CTC TCT AGT AGA CAA TCC CGT GCT
AAA TGC CTA ACG ACT ATC CCT T, Th1P6 GCC TGA
GTA TAA GGT GAC TTA TAC TTG TAA TCT ATC TAA ACG
GGG AAC CTC TCT AGT AGA CAA TCC CGT GCT AAA
TTA TAC CAG CAT CGT CTT GAT GCC CTT GGC AGA
TAA ATG CCT AAC GAC TAT CCC TT, Th2P6 GCC TGA
GTA TAA GGT GAC TTA TAC TTG TAA TCT ATC TAA ACG
GGG AAC CTC TCT AGT AGA CAA TCC CGT GCT AAA
TTG ATA CCA GCA TCG TCT TGA TGC CCT TGG CAG
CAT AAA TGC CTA ACG ACT ATC CCT T, Th3P6 GCC
TGA GTA TAA GGT GAC TTA TAC TTG TAA TCT ATC TAA
ACG GGG AAC CTC TCT AGT AGA CAA TCC CGT GCA
TAC CAG CAT CGT CTT GAT GCC CTT GGC AGG CCT
AAC GAC TAT CCC TT, Th4P6 GCC TGA GTA TAA GGT
GAC TTA TAC TTG TAA TCT ATC TAA ACG GGG AAC
CTC TCT AGT AGA CAA TCC CGT GCT AAA TAT ACC
AGC ATC GTC TTG ATG CCC TTG GCA GTA AAT GCC
TAA CGA CTA TCC CTT, Th5P6 GCC TGA GTA TAA GGT
GAC TTA TAC TTG TAA TCT ATC TAA ACG GGG AAC
CTC TCT AGT AGA CAA TCC CGT ATA CCA GCA TCG
TCT TGA TGC CCT TGG CAG CTA ACG ACT ATC CCT T,
Th6P6 GCC TGA GTA TAA GGT GAC TTA TAC TTG TAA
TCT ATC TAA ACG GGG AAC CTC TCT AGT AGA CAA
TCC CGT GAT ACC AGC ATC GTC TTG ATG CCC TTGBMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/21
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GCA GCC TAA CGA CTA TCC CTT, Th1P5 TGA GTA TAA
GGT GAC TTA TAC TAG TAA TCT ATC TAA ACG GGG
AAC CTC TAT ACC AGC ATC GTC TTG ATG CCC TTG
GCA GAG ACA ATC CCG TGC TAA ATT GTA GGA CTG
CCC GGG TTC TAC ATA AAT GCC TAA CGA CTA TCC
CTT, Th2P5 TGA GTA TAA GGT GAC TTA TAC TAG TAA
TCT ATC TAA ACG GGG AAC CTA TAC CAG CAT CGT
CTT GAT GCC CTT GGC AGA CAA TCC CGT GCT AAA
TTG TAG GAC TGC CCG GGT TCT ACA TAA ATG CCT
AAC GAC TAT CCC TT, 3Mex2P6 GTA ATC TAT CTA AAC
GGG GAA CCT CTC TAG TAG ACA ATC CCG TGC TAA
ATT GAT ACC AGC ATC GTC TTG ATG CCA TTG GCA
GCA TAA ATG CCT AAC GAC TAT CCC TT, and Th2P6.D
GTA ATC TAT CTA AAC GGG GAA CCT CTC TAG TAG
ACA ATC CCG TGC TAA ATT GAT ACC AGC ATC GTC
TTG ATG CCC TTG GTT GCA TAA ATG CCT AAC GAC
TAT CCC TT.
In vitro transcription
The introns were PCR-amplified with KM37 (GAT AAT
ACG ACT CAC TAT AAT GGC ATT ACC GCC TTG T) and
GM24 (GCT CTA GAC TTA GCT ACA ATA TGA AC) in 25
µl reactions under the conditions stated above and cycled
20 times. A portion of the reaction (5 µl) was run on a 3%
agarose gel and the PCR product band was stabbed with a
pipette tip. The agarose plug was added to a fresh PCR re-
action (100 µl) and cycled 15 times; DNA was purified us-
ing a QIAquick kit and quantitated. The PCR product (2
µg in 50 µl) was added to an in vitro transcription reaction
containing Ampliscribe T7 RNA polymerase (Epicentre),
RNase inhibitor (GIBCO BRL, Rockville, MD; 5 units),
low Mg2+ buffer (30 mM Tris-HCl, pH 8, 7.5 mM DTT, 4.5
mM MgCl2, 1.5 mM spermidine), UTP (1.25 mM), ATP
(2.5 mM), GTP (2.5 mM), CTP (7.5 mM) and α-32P UTP
(NEN, Boston, MA; 20 µCi; 3000 mCi/mmol), and incu-
bated at 37°C for 2 hours. DNase (GIBCO BRL, 295 units)
was added and the reaction was incubated at 37°C for an
additional 30 minutes. The RNA was purified using Cen-
tri-Sep columns (Princeton Separations, Adelphia, NJ)
and quantitated.
In vitro splicing assays
The assays were performed by heating the RNA (500 nM)
in H2O to 70°C for 3 minutes then transferring to ice for
1 minute. Splicing buffer (20 mM Tris-HCl, pH 7.5, 100
mM KCl, 3 mM MgCl2), effector (theophylline, 1.5 mM)
was added and the reactions were incubated on ice for an
additional 15 minutes. At this time a 4.5 µl aliquot was re-
moved for a zero time point and quenched with 5 µl stop
dye (95% formamide, 20 mM EDTA, 0.5% xylene cyanol,
and 0.5% bromophenol blue). GTP (50 µM) was added to
the remaining reaction (5 µl total volume) to start the
splicing reaction. The reaction was incubated at 37°C for
30 minutes and then terminated with stop dye (5 µl). The
reactions were heated to 70°C for 3 minutes and 5 µl was
analyzed on a 8% denaturing polyacrylamide gel. The gel
was dried, exposed to a phosphor screen and analyzed us-
ing a Molecular Dynamics Phosphorimager (Sunnyvale,
CA).
The reaction volumes were increased for the rate determi-
nation assay. Aliquots were taken at intervals between 0
minutes and 15 minutes and terminated with stop dye.
The reactions were analyzed as described above. For each
time point, the number of counts in unreacted intron,
spliced intron, and circularized intron were determined.
Background counts were subtracted from these values.
The fraction of reacted intron was then calculated as:
(circular intron + spliced intron) / (unreacted intron + cir-
cular intron + spliced intron)
The individual time points were averaged together, the
fraction reacted was plotted versus time, and rate con-
stants were extracted by fitting the data to a single-expo-
nential equation:
F = A * e(-kt)
The plotted data and rate constants for Th1P5 and Th2P6
constructs are shown in Figures 2b and 2c and Table 2.
The changes in the extent of reaction observed between in-
dividual experiments, and thus the attendant error bars,
were consistent with those observed during the kinetic
analyses of other ribozymes. For example, studies of the
hairpin ribozyme have shown that data points can vary
between individual experiments by as much as 50% [40].
Our data points typically varied from one another by less
than 30%.
In vivo plate assay
The plasmids containing the various group I constructs
were transformed into competent C600ThyA::KanR cells
and grown in LB with kanamycin overnight. A small aliq-
uot (3 µl) of overnight cell culture was mixed with effector
(theophylline, 7.5 mM) or H2O, spotted on plates, and
grown overnight at 37°C. As a positive control, all con-
structs were also plated on minimal media plates with
thymine (MMT) and assayed for viability.
In vivo growth curves
Cells grown overnight in LB were diluted 1:100 in MM
containing either theophylline, caffeine, 3-methylxan-
thine or no effector, and analyzed on a Microbiology
Workstation Bioscreen C (Labsystems, Inc., Franklin,
MA).
RT-PCR analysis
RNA was isolated from an overnight culture using a Mas-
terPure RNA purification kit (Epicentre, Madison, WI)BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/21
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and amplified by RT-PCR using primers KM37 and GM24
following the protocol provided for Tth polymerase. The
products were separated and analyzed on a 3% agarose
gel.
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